Alternatives to Bariatric Surgery, Ranked by Evidence
A review's one hedged sentence about GLP-1 drugs and surgery, read like a contract, and what each clause actually commits anyone to.

One thing that happens when a field gets a powerful new tool is that every paper about the old tool grows a sentence explaining where the new tool fits, and that sentence tries to fit it everywhere at once. Bariatric surgery got its new tool in GLP-1 drugs, and a focused review titled “Long-Term Effects of Bariatric Surgery on Type 2 Diabetes” wrote the sentence: GLP-1 receptor agonists and dual GIP/GLP-1 therapies “may serve as alternatives, bridges, or postoperative adjuncts to bariatric surgery for T2DM, though post-surgical evidence remains limited.” This post reads that sentence the way you would read a contract, clause by clause, because in some sense it is the whole field in 25 words.
First, the plain answer. The alternatives to bariatric surgery with real comparative evidence behind them are GLP-1-type drugs (semaglutide and tirzepatide), endoscopic sleeve gastroplasty (ESG), and intragastric balloons. Where those alternatives have been measured against surgery, surgery wins: a 2026 systematic review found it beat incretin drugs on every primary outcome it measured, and a network meta-analysis of randomized trials found ESG beat the balloons at 12 months.
What the alternatives to bariatric surgery actually are, by evidence
Ranked by how much evidence stands behind them, the list goes like this. Surgery itself has the deepest record, including data at 10 years and beyond. The drugs have a head-to-head systematic review against surgery. ESG and balloons have randomized trials against each other, ranked at 12 months. Combinations (a drug plus an endoscopic procedure, a drug after surgery) have the thinnest evidence, mostly reviews and trials still reporting.
That is the overview. The rest is the sentence, because the sentence explains why the overview looks the way it does. (Individual procedures get their own articles elsewhere on this site.)
What “may serve” commits anyone to
In a contract, “may” grants permission and imposes no obligation. A landlord who “may” fix the roof has promised nothing about the roof. So the first clause says GLP-1 drugs are permitted to serve as alternatives to surgery. It does not say they do.
Then comes the list of roles: “alternatives, bridges, or postoperative adjuncts.” These are three different jobs. An alternative is instead of surgery. A bridge comes before it. An adjunct comes after. It is a bit like a friend who offers to drive you to the airport, or to the train station that goes to the airport, or to pick you up when you land, and who has so far only done the third one twice. The drug in this sentence is a utility infielder, listed at short, second and third, with no starting position.
The sexy word in the sentence is “alternatives.” The word doing the work is “limited.”
Also, “for T2DM.” Read literally, the whole sentence is scoped to type 2 diabetes, not to weight. (Diabetes remission has its own article here.) And the same review says nearly the same thing twice, once as “adjuncts to bariatric surgery” and once as adjuncts “alongside bariatric surgery.” “To” implies the drug is attached to the operation. “Alongside” implies they merely share a room. I don’t know which one the authors meant. Possibly both, lol.
How strong the evidence for drugs as an alternative is
The “alternatives” clause has the most evidence behind it, and that evidence mostly says no. A 2026 PRISMA-compliant systematic review of incretin-based therapies versus bariatric and metabolic surgery found 14 studies (8 randomized trials, 6 matched cohorts, 25,566 people) published between January 2014 and April 2026. Its conclusion, in its own words, was that surgery “demonstrated superiority over incretin-based therapies across all five primary outcome domains”: diabetes remission, weight reduction, heart attacks and deaths, fatty liver resolution, and quality of life.
The numbers are not close. Surgery achieved diabetes remission in 23 to 70 percent of patients, compared with 0 percent on incretin drugs. Five-year weight loss was 25 to 32 percent after surgery against 14.9 to 20.9 percent on semaglutide or tirzepatide. The pooled relative risk of major cardiovascular events for surgery versus GLP-1 drugs was 0.48. (Six of the 14 studies were matched cohorts rather than randomized trials, which is worth holding in mind with any number that confident.) The facts here also do not say how remission was counted for patients still taking a diabetes drug, which matters a great deal for a number like zero.
Surgery is not one thing, either. At 10 years, average total weight loss ranges from 24.4 percent for the sleeve to roughly 40 percent for the duodenal switch. And diabetes “remission” after surgery leaks: in one cohort of 2,197 patients with diabetes, 93.6 percent got at least 90 days off diabetes medication, and 42.9 percent of those later went back on it, with a median of about a year before they did. Bypass patients were less likely to restart than sleeve patients (hazard ratio 0.778).
The bridge clause has a little evidence. One single-center retrospective study found patients on GLP-1 drugs before surgery lost a median 9.0 kg beforehand, against 5.0 kg with no drug. That is a bridge that holds weight. It is also one study.
Where endoscopic sleeves and balloons rank
The endoscopic options are not in the sentence at all, which is its own literal reading: they are the alternatives that do not even get a “may.” Their evidence lives elsewhere. A network meta-analysis of randomized trials found ESG “ranked highest for weight loss efficacy at 12-month follow-up,” with a P-score of 0.899, ahead of the Spatz3 and Orbera balloons.
A P-score is a rank, not a size. It tells you ESG came first, not by how much, and 12 months is a short contract term for a disease measured in decades. How ESG or balloons compare with surgery over 10 years is, on these facts, not settled.
There is one interesting crossover. A scoring tool built to predict diabetes remission after surgery (the IMS score) also predicted it after ESG: 60 percent remission in mild cases, 45.5 percent in moderate, 0 percent in severe. The same predictors (shorter diabetes duration, lower starting HbA1c, preserved beta-cell function) show up for surgery and for GLP-1 drugs too. Which suggests, in some sense, that the patient is a bigger variable than the procedure.
What “post-surgical evidence remains limited” leaves open
The adjunct clause is where the sentence admits it is mostly a promise. The BARI-STEP trial is testing semaglutide 2.4 mg once weekly against placebo in people with “suboptimal clinical response” after surgery, defined as less than 20 percent weight loss. The facts here describe its design, not its results. Limited indeed.
A systematic review found that adding liraglutide to endoscopic therapy produced weight loss comparable to surgery’s net weight loss, meaning its lowest weight minus what was regained. Read literally, the comparison is to surgery after some of it wore off. It’s fine. It is just a specific benchmark.
Here is an invented patient, purely hypothetical. She starts a GLP-1 drug as a bridge, loses weight, has a sleeve, regains some, goes back on the drug as an adjunct, has an endoscopic procedure on top, and continues the drug alongside that. At every step the drug was serving in one of its three permitted roles. By the end it has been her alternative, her bridge, and her adjunct, and the review’s sentence covers all of it, presumably without having predicted any of it.
Why everyone writes the sentence this way
Everyone involved is behaving sensibly. Review authors hedge because the post-surgical trials have not reported, and “may” is the honest word for that. Surgeons point to the head-to-head data because it favors them. Patients want the option with the fewest incisions that still works, which is a reasonable thing to want. And the drug’s real appeal is that it is willing to partner with almost any procedure, which is a commercially attractive quality in a product.
I assume the conversation in the clinic sounds something like: “So this can be instead of the operation, or before it, or after it, and we’ll see which.” I mean, that is accurate. It is just three answers.
Read clause by clause, then, the sentence says the drug may be an alternative to surgery, which the best head-to-head evidence says it mostly isn’t yet, or a bridge, which one study supports, or an adjunct, which trials are still testing, etc. Read the contract all the way to the end and the best-documented alternative to bariatric surgery, for the 5 to 8 percent of patients whose first operation does not work, is a second bariatric surgery. So the sentence can be kept word for word with a new subject: surgery may serve as an alternative, bridge, or postoperative adjunct to surgery, and of all its versions that is the one the evidence covers best.
Sources
- Long-Term Effects of Bariatric Surgery on Type 2 Diabetes: Mechanisms, Outcomes, and Clinical Implications: A Focused Review
- Baseline Diabetes Severity Is the Dominant Predictor of Diabetes Medication Re-Initiation Following Bariatric Surgery
- Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes
- Comparative effectiveness of balloons, adjustable balloons, and endoscopic sleeve gastroplasty: a network meta-analysis of randomized trials
- Lifestyle Modification and Bariatric Surgery in Type 2 Diabetes Remission : Short title: Diabetes Remission Strategies in T2DM
- Advances in Metabolic Bariatric Surgeries and Endoscopic Therapies: A Comprehensive Narrative Review of Diabetes Remission Outcomes
- Applicability of individualized metabolic surgery score for prediction of diabetes remission after endoscopic sleeve gastroplasty
- A Comprehensive Review of Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, One-Anastomosis Gastric Bypass, Duodenal Switch, and SADI-S: Very Long-Term Outcomes at 10 Years and Beyond
- Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Does Preoperative GLP-1 Therapy Improve Postoperative Bariatric Surgery Outcomes? A Single-Centre Retrospective Observational Study
- Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
- Laparoscopic Single Anastomosis Duodeno-Ileal Bypass Versus One Anastomosis Gastric Bypass as Revisional Procedures after Sleeve Gastrectomy: Meta-analysis and Systematic Review
Bariatric Alt explains published research. It is not medical advice, and it never recommends a surgeon, a clinic, a dose or a product. Talk to a clinician about which option fits you.